Eli Lilly
Biocartis, Eli Lilly Partner for Spanish NSCLC Biomarker Study
The study aims to establish how Biocartis' Idylla molecular testing platform can eventually be used to improve community-based diagnostic workflows in the US.
Alzheimer's Dx Firms Aim to Take Advantage of Increased Testing Demand Following Leqembi Approval
Premium
Near term, CSF assays and PET imaging will likely remain the methods of choice for evaluating patients for the drug, but blood tests continue to gain traction.
Amoy Diagnostics PLC Panel Gets Approval in Japan as CDx for Retevmo in Non-Small Cell Lung Cancer
Oncologists in Japan can now use the AmoyDx Pan Lung Cancer PCR Panel to identify patients with RET fusions that make them eligible for treatment with the Eli Lilly drug.
Roche, Eli Lilly Collaborate on Blood Test to Aid Early Diagnosis of Alzheimer's
Produced by Roche, the test measures phosphorylated tau 181 protein and apolipoprotein E4 to help determine if an individual is at high risk of Alzheimer's.
OncoDNA, Eli Lilly Partner on Thyroid Cancer Biomarker Testing
The companies are working together to offer next-generation sequencing-based molecular testing on thyroid cancer biopsies to clinicians in Italy.